|Preferred IUPAC name
3D model (JSmol)
CompTox Dashboard (EPA)
|Molar mass||125.14 g/mol|
|Appearance||colorless or white solid|
|Density||1.734 g/cm3 (at −173.15 °C)|
|Melting point||305.11 °C (581.20 °F; 578.26 K) Decomposes into simple molecules|
|Acidity (pKa)||<0, 9.06|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Taurine (//), or 2-aminoethanesulfonic acid, is an organic compound that is widely distributed in animal tissues. It is a major constituent of bile and can be found in the large intestine, and accounts for up to 0.1% of total human body weight. Taurine is named after the Latin taurus (a cognate of the Greek ταῦρος) which means bull or ox, as it was first isolated from ox bile in 1827 by German scientists Friedrich Tiedemann and Leopold Gmelin. It was discovered in human bile in 1846 by Edmund Ronalds.
Taurine has many biological roles, such as conjugation of bile acids, antioxidation, osmoregulation, membrane stabilization, and modulation of calcium signaling. It is essential for cardiovascular function, and development and function of skeletal muscle, the retina, and the central nervous system.
Taurine is an unusual example of a naturally occurring sulfonic acid.
Chemical and biochemical features
Taurine exists as a zwitterion H3N+CH2CH2SO3−, as verified by X-ray crystallography. The sulfonic acid has a low pKa ensuring that it is fully ionized to the sulfonate at the pH's found in the intestinal tract.
Synthetic taurine is obtained by the ammonolysis of isethionic acid (2-hydroxyethanesulfonic acid), which in turn is obtained from the reaction of ethylene oxide with aqueous sodium bisulfite. A direct approach involves the reaction of aziridine with sulfurous acid.
In 1993, about 5,000–6,000 tons of taurine were produced for commercial purposes: 50% for pet food and 50% in pharmaceutical applications. As of 2010, China alone has more than 40 manufacturers of taurine. Most of these enterprises employ the ethanolamine method to produce a total annual production of about 3,000 tons.
In the laboratory taurine can be produced by alkylation of ammonia with bromoethanesulfonate salts.
Taurine is naturally derived from cysteine. Mammalian taurine synthesis occurs in the pancreas via the cysteine sulfinic acid pathway. In this pathway, cysteine is first oxidized to its sulfinic acid, catalyzed by the enzyme cysteine dioxygenase. Cysteine sulfinic acid, in turn, is decarboxylated by sulfinoalanine decarboxylase to form hypotaurine. Hypotaurine is enzymatically oxidized to yield taurine by hypotaurine dehydrogenase.
Taurine is also produced by the transsulfuration pathway, which converts homocysteine into cystathionine. The cystathionine is then converted to hypotaurine by the sequential action of three enzymes: cystathionine gamma-lyase, cysteine dioxygenase, and cysteine sulfinic acid decarboxylase. Hypotaurine is then oxidized to taurine as described above.
Oxidative degradation of cysteine to taurine
Taurine occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg (range from 9 to 372 mg) and to be low or negligible from a strict vegan diet. In another study, taurine intake was estimated to be generally less than 200 mg/day, even in individuals eating a high-meat diet. According to a third study, taurine consumption was estimated to vary between 40 and 400 mg/day.
Prematurely born infants are believed to lack the enzymes needed to convert cystathionine to cysteine, and may, therefore, become deficient in taurine. Taurine is present in breast milk, and has been added to many infant formulas, as a measure of prudence, since the early 1980s. However, this practice has never been rigorously studied, and as such it has yet to be proven to be necessary, or even beneficial.
Taurine is essential for cardiovascular function and development and function of skeletal muscle, the retina, and the central nervous system. It is a biosynthetic precursor to the bile salts sodium taurochenodeoxycholate and sodium taurocholate.
Taurine functions as an antioxidant, suppressing the toxicity of hypochlorite and hypobromite produced physiologically. Taurine reacts with these halogenating agents to form N-chloro- and N-bromotaurine, which are less toxic than their precursors hypohalides.
Role in nutrition and cardiovascular health
Taurine has been shown to reduce the secretion of apolipoprotein B100 and lipids in HepG2 cells. High concentrations of serum lipids and apolipoprotein B100 (essential structural component of VLDL and LDL) are major risk factors of atherosclerosis and coronary heart disease. Hence, taurine supplementation is possibly beneficial for the prevention of these diseases.
Role in the muscular system
Taurine is necessary for normal skeletal muscle functioning. Mice with a genetic taurine deficiency had a nearly complete depletion of skeletal and cardiac muscle taurine levels and a reduction of more than 80% of exercise capacity compared to control mice. Taurine can influence (and possibly reverse) defects in nerve blood flow, motor nerve conduction velocity, and nerve sensory thresholds in experimental diabetic neuropathic rats.
Taurine crosses the blood–brain barrier and has been implicated in a wide array of physiological phenomena including inhibitory neurotransmission, long-term potentiation in the striatum/hippocampus, membrane stabilization feedback inhibition of neutrophil/macrophage respiratory burst, adipose tissue regulation and possible prevention of obesity, calcium homeostasis, recovery from osmotic shock, protection against glutamate excitotoxicity, and prevention of epileptic seizures.
According to the single study on human subjects, daily administration of 1.5 g of taurine had no significant effect on insulin secretion or insulin sensitivity. There is evidence that taurine may exert a beneficial effect in preventing diabetes-associated microangiopathy and tubulointerstitial injury in diabetic nephropathy.
Taurine acts as a glycation inhibitor. Taurine-treated diabetic rats had a decrease in the formation of advanced glycation end products (AGEs) and AGEs content. The United States Department of Agriculture has found a link between cataract development and lower levels of vitamin B6, folate, and taurine in the diets of the elderly.
Animal physiology and nutrition
In diabetic rats, taurine supplementation slightly reduced abdominal body fat while improving glucose tolerance. Taurine is effective in removing fatty liver deposits in rats, preventing liver disease, and reducing cirrhosis in tested animals. Evidence indicates taurine may be beneficial for blood pressure in male rats. A single intravenous taurine supplementation resulted in measurable decreases in blood pressure. However, when rats were supplemented with taurine in their drinking water, only female rats showed an increase in blood pressure. Both genders showed significant tachycardia.
Cats lack the enzymatic machinery (sulfinoalanine decarboxylase) to produce taurine and must therefore acquire it from their diet. A taurine deficiency in cats can lead to retinal degeneration and eventually blindness. Other effects of a diet lacking in this essential amino acid are dilated cardiomyopathy and reproductive failure in females. The absence of taurine causes a cat's retina to slowly degenerate, causing eye problems and (eventually) irreversible blindness – a condition known as central retinal degeneration (CRD), as well as hair loss and tooth decay. Decreased plasma taurine concentration has been demonstrated to be associated with feline dilated cardiomyopathy. Unlike CRD, the condition is reversible with supplementation. Taurine is now a requirement of the Association of American Feed Control Officials (AAFCO) and any dry or wet food product labeled approved by the AAFCO should have a minimum of 0.1% taurine in dry food and 0.2% in wet food. Studies suggest the amino acid should be supplied at 10 mg/kg of bodyweight/day for domestic cats.
Taurine appears essential to the development of passerine birds. Many passerines seek out taurine-rich spiders to feed their young, particularly just after hatching. Researchers compared the behaviours and development of birds fed a taurine-supplemented diet to a control diet and found the juveniles fed taurine-rich diets as neonates were much larger risk takers and more adept at spatial learning tasks.
Safety and toxicity
A substantial increase in the plasma concentration of growth hormone was reported in some epileptic patients during taurine tolerance testing (oral dose of 50 mg per kg body mass per day), suggesting a potential to stimulate the hypothalamus and to modify neuroendocrine function. A 1966 study found an indication that taurine (2 g/day) has some function in the maintenance and possibly in the induction of psoriasis. Three later studies failed to support that finding. It may also be necessary to take into consideration that absorption of taurine from beverages may be more rapid than from foods.
Taurine has an observed safe level of supplemental intake in normal healthy adults at up to 3 g/day. Even so, a study by the European Food Safety Authority found no adverse effects for up to 1,000 mg of taurine per kilogram of body weight per day.
A review published in 2008 found no documented reports of negative or positive health effects associated with the amount of taurine used in energy drinks, concluding, "The amounts of guarana, taurine, and ginseng found in popular energy drinks are far below the amounts expected to deliver either therapeutic benefits or adverse events".
In cosmetics and contact lens solutions
Since the 2000s cosmetic compositions containing taurine have been introduced, possibly due to its antifibrotic properties. It has been shown to prevent the damaging effects of TGFB1 to hair follicles. It also helps to maintain skin hydration.
Taurine is also used in some contact lens solutions.
- Taurine is used in the preparation of the anthelmintic drug netobimin (Totabin).
- Taurocholic acid and tauroselcholic acid
- 5-Taurinomethyluridine and 5-taurinomethyl-2-thiouridine are modified uridines in (human) mitrochondrial tRNA.
- Tauryl is the functional group attaching at the sulfur, 2-aminoethylsulfonyl.
- Taurino is the functional group attaching at the nitrogen, 2-sulfoethylamino.
- Schuller-Levis GB, Park E (September 2003). "Taurine: new implications for an old amino acid". FEMS Microbiology Letters. 226 (2): 195–202. doi:10.1016/S0378-1097(03)00611-6. PMID 14553911.
- Tiedemann F, Gmelin L (1827). "Einige neue Bestandtheile der Galle des Ochsen". Annalen der Physik. 85 (2): 326–37. Bibcode:1827AnP....85..326T. doi:10.1002/andp.18270850214.
- Ronalds BF (2019). "Bringing Together Academic and Industrial Chemistry: Edmund Ronalds' Contribution". Substantia. 3 (1): 139–152.
- Görbitz CH, Prydz K, Ugland S (2000). "Taurine". Acta Crystallographica Section C. 56: e23–e24. doi:10.1107/S0108270199016029.
- Irving CS, Hammer BE, Danyluk SS, Klein PD (October 1980). "13C nuclear magnetic resonance study of the complexation of calcium by taurine". Journal of Inorganic Biochemistry. 13 (2): 137–50. doi:10.1016/S0162-0134(00)80117-8. PMID 7431022.
- Kosswig K (2000). "Sulfonic Acids, Aliphatic". Ullmann's Encyclopedia of Industrial Chemistry. Weinheim: Wiley-VCH. doi:10.1002/14356007.a25_503.
- Tully PS, ed. (2000). "Sulfonic Acids". Kirk-Othmer Encyclopedia of Chemical Technology. John Wiley & Sons, Inc. doi:10.1002/0471238961.1921120620211212.a01. ISBN 978-0471238966.
- Amanda Xia (2010-01-03). "China Taurine Market Is Expected To Recover". Press release and article directory: technology. Archived from the original on 2018-09-20. Retrieved 2010-05-24.
- Marvel CS, Bailey CF, Cortese F (1938). "Taurine". Org. Synth. 18: 77. doi:10.15227/orgsyn.018.0077.
- Sumizu K (September 1962). "Oxidation of hypotaurine in rat liver". Biochimica et Biophysica Acta. 63: 210–2. doi:10.1016/0006-3002(62)90357-8. PMID 13979247.
- Ripps H, Shen W (2012). "Review: taurine: a "very essential" amino acid". Molecular Vision. 18: 2673–86. PMC 3501277. PMID 23170060.
- Bouckenooghe T, Remacle C, Reusens B (November 2006). "Is taurine a functional nutrient?". Current Opinion in Clinical Nutrition and Metabolic Care. 9 (6): 728–33. doi:10.1097/01.mco.0000247469.26414.55. PMID 17053427. S2CID 24064647.
- Brosnan JT, Brosnan ME (June 2006). "The sulfur-containing amino acids: an overview". The Journal of Nutrition. 136 (6 Suppl): 1636S–1640S. doi:10.1093/jn/136.6.1636S. PMID 16702333.
- Huxtable RJ (January 1992). "Physiological actions of taurine". Physiological Reviews. 72 (1): 101–63. doi:10.1152/physrev.19184.108.40.206. PMID 1731369. S2CID 27844955.
- "Opinion on Caffeine, Taurine and D-Glucurono — g -Lactone as constituents of so-called 'energy' drinks". Directorate-General Health and Consumers, European Commission, European Union. 1999-01-21. Archived from the original on 2006-06-23.
- Jacobson SG, Kemp CM, Borruat FX, Chaitin MH, Faulkner DJ (October 1987). "Rhodopsin topography and rod-mediated function in cats with the retinal degeneration of taurine deficiency". Experimental Eye Research. 45 (4): 481–90. doi:10.1016/S0014-4835(87)80059-3. PMID 3428381.
- Laidlaw SA, Shultz TD, Cecchino JT, Kopple JD (April 1988). "Plasma and urine taurine levels in vegans". The American Journal of Clinical Nutrition. 47 (4): 660–3. doi:10.1093/ajcn/47.4.660. PMID 3354491.
- Heird WC (November 2004). "Taurine in neonatal nutrition--revisited". Archives of Disease in Childhood. Fetal and Neonatal Edition. 89 (6): F473-4. doi:10.1136/adc.2004.055095. PMC 1721777. PMID 15499132.
- rockstar69.com Original Rockstar Ingredients
- Chang, PL (2008-05-03). "Nos Energy Drink – Review". energyfanatics.com. Archived from the original on 2008-06-17. Retrieved 2010-05-21.
- Huxtable RJ (January 1992). "Physiological actions of taurine". Physiological Reviews. 72 (1): 101–63. doi:10.1152/physrev.19220.127.116.11. PMID 1731369. S2CID 27844955.
- Marcinkiewicz J, Kontny E (January 2014). "Taurine and inflammatory diseases". Amino Acids. 46 (1): 7–20. doi:10.1007/s00726-012-1361-4. PMC 3894431. PMID 22810731.
- Yanagita T, Han SY, Hu Y, Nagao K, Kitajima H, Murakami S (October 2008). "Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells". Lipids in Health and Disease. 7: 38. doi:10.1186/1476-511x-7-38. PMC 2579289. PMID 18925970.
- Warskulat U, Flögel U, Jacoby C, Hartwig HG, Thewissen M, Merx MW, et al. (March 2004). "Taurine transporter knockout depletes muscle taurine levels and results in severe skeletal muscle impairment but leaves cardiac function uncompromised" (PDF). FASEB Journal. 18 (3): 577–9. doi:10.1096/fj.03-0496fje. PMID 14734644. S2CID 19037998.
- Li F, Abatan OI, Kim H, Burnett D, Larkin D, Obrosova IG, Stevens MJ (June 2006). "Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats". Neurobiology of Disease. 22 (3): 669–76. doi:10.1016/j.nbd.2006.01.012. PMID 16624563. S2CID 22502432.
- Pop-Busui R, Sullivan KA, Van Huysen C, Bayer L, Cao X, Towns R, Stevens MJ (April 2001). "Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits". Experimental Neurology. 168 (2): 259–72. doi:10.1006/exnr.2000.7591. PMID 11259114. S2CID 28261875.
- Urquhart N, Perry TL, Hansen S, Kennedy J (May 1974). "Passage of taurine into adult mammalian brain". Journal of Neurochemistry. 22 (5): 871–2. doi:10.1111/j.1471-4159.1974.tb04309.x. PMID 4407108. S2CID 32864924.
- Tsuji A, Tamai I (1996). "Sodium- and chloride-dependent transport of taurine at the blood-brain barrier". Taurine 2. Advances in Experimental Medicine and Biology. 403. pp. 385–91. doi:10.1007/978-1-4899-0182-8_41. ISBN 978-1-4899-0184-2. PMID 8915375.
- Salimäki J, Scriba G, Piepponen TP, Rautolahti N, Ahtee L (August 2003). "The effects of systemically administered taurine and N-pivaloyltaurine on striatal extracellular dopamine and taurine in freely moving rats". Naunyn-Schmiedeberg's Archives of Pharmacology. 368 (2): 134–41. doi:10.1007/s00210-003-0776-6. PMID 12898127. S2CID 24364099.
- Olive MF (2002). "Interactions between taurine and ethanol in the central nervous system". Amino Acids. 23 (4): 345–57. doi:10.1007/s00726-002-0203-1. PMID 12436202. S2CID 5406826.
- Dominy J, Thinschmidt JS, Peris J, Dawson R, Papke RL (June 2004). "Taurine-induced long-lasting potentiation in the rat hippocampus shows a partial dissociation from total hippocampal taurine content and independence from activation of known taurine transporters". Journal of Neurochemistry. 89 (5): 1195–205. doi:10.1111/j.1471-4159.2004.02410.x. PMID 15147512. S2CID 5461179.
- Schaffer SW, Jong CJ, Ramila KC, Azuma J (August 2010). "Physiological roles of taurine in heart and muscle". Journal of Biomedical Science. 17 Suppl 1 (Suppl 1): S2. doi:10.1186/1423-0127-17-S1-S2. PMC 2994395. PMID 20804594.
- Ide T, Kushiro M, Takahashi Y, Shinohara K, Cha S (September 2002). "mRNA expression of enzymes involved in taurine biosynthesis in rat adipose tissues". Metabolism: Clinical and Experimental. 51 (9): 1191–7. doi:10.1053/meta.2002.34036. PMID 12200766.
- Tsuboyama-Kasaoka N, Shozawa C, Sano K, Kamei Y, Kasaoka S, Hosokawa Y, Ezaki O (July 2006). "Taurine (2-aminoethanesulfonic acid) deficiency creates a vicious circle promoting obesity". Endocrinology. 147 (7): 3276–84. doi:10.1210/en.2005-1007. PMID 16627576.
- Foos TM, Wu JY (February 2002). "The role of taurine in the central nervous system and the modulation of intracellular calcium homeostasis". Neurochemical Research. 27 (1–2): 21–6. doi:10.1023/A:1014890219513. PMID 11926272. S2CID 29948337.
- Stummer W, Betz AL, Shakui P, Keep RF (September 1995). "Blood-brain barrier taurine transport during osmotic stress and in focal cerebral ischemia". Journal of Cerebral Blood Flow and Metabolism. 15 (5): 852–9. doi:10.1038/jcbfm.1995.106. PMID 7673378.
- Leon R, Wu H, Jin Y, Wei J, Buddhala C, Prentice H, Wu JY (April 2009). "Protective function of taurine in glutamate-induced apoptosis in cultured neurons". Journal of Neuroscience Research. 87 (5): 1185–94. doi:10.1002/jnr.21926. PMID 18951478. S2CID 24725862.
- El Idrissi A, Messing J, Scalia J, Trenkner E (2003). "Prevention of epileptic seizures by taurine". Taurine 5. Advances in Experimental Medicine and Biology. 526. pp. 515–25. doi:10.1007/978-1-4615-0077-3_62. ISBN 978-1-4613-4913-6. PMID 12908638.
- Brøns C, Spohr C, Storgaard H, Dyerberg J, Vaag A (September 2004). "Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus". European Journal of Clinical Nutrition. 58 (9): 1239–47. doi:10.1038/sj.ejcn.1601955. PMID 15054439. S2CID 2199220.
- Wu QD, Wang JH, Fennessy F, Redmond HP, Bouchier-Hayes D (December 1999). "Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis". The American Journal of Physiology. 277 (6): C1229-38. doi:10.1152/ajpcell.1999.277.6.C1229. PMID 10600775.
- Verzola D, Bertolotto MB, Villaggio B, Ottonello L, Dallegri F, Frumento G, et al. (November 2002). "Taurine prevents apoptosis induced by high ambient glucose in human tubule renal cells". Journal of Investigative Medicine. 50 (6): 443–51. doi:10.2310/6650.2002.32504. PMID 12425431.
- Kong WX, Chen SW, Li YL, Zhang YJ, Wang R, Min L, Mi X (February 2006). "Effects of taurine on rat behaviors in three anxiety models". Pharmacology, Biochemistry, and Behavior. 83 (2): 271–6. doi:10.1016/j.pbb.2006.02.007. PMID 16540157. S2CID 30644212.
- Zhang CG, Kim SJ (2007). "Taurine induces anti-anxiety by activating strychnine-sensitive glycine receptor in vivo". Annals of Nutrition & Metabolism. 51 (4): 379–86. doi:10.1159/000107687. PMID 17728537. S2CID 10017887.
- Chen SW, Kong WX, Zhang YJ, Li YL, Mi XJ, Mu XS (August 2004). "Possible anxiolytic effects of taurine in the mouse elevated plus-maze". Life Sciences. 75 (12): 1503–11. doi:10.1016/j.lfs.2004.03.010. PMID 15240184.
- Effects of taurine on advanced glycosylation end products and expression of TGF-β in renal cortex of, TsingHua, 2005, http://www.shvoong.com/medicine-and-health/1599878-effects-taurine-advanced-glycosylation-end/
- Huang JS, Chuang LY, Guh JY, Yang YL, Hsu MS (December 2008). "Effect of taurine on advanced glycation end products-induced hypertrophy in renal tubular epithelial cells". Toxicology and Applied Pharmacology. 233 (2): 220–6. doi:10.1016/j.taap.2008.09.002. PMID 18834896.
- "ARS: 50 Years of Research for the Growing World". Ars.usda.gov. Retrieved 2012-10-27.
- Nakaya Y, Minami A, Harada N, Sakamoto S, Niwa Y, Ohnaka M (January 2000). "Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes". The American Journal of Clinical Nutrition. 71 (1): 54–8. doi:10.1093/ajcn/71.1.54. PMID 10617946.
- Kerai MD, Waterfield CJ, Kenyon SH, Asker DS, Timbrell JA (1998). "Taurine: protective properties against ethanol-induced hepatic steatosis and lipid peroxidation during chronic ethanol consumption in rats". Amino Acids. 15 (1–2): 53–76. doi:10.1007/BF01345280. PMID 9871487. S2CID 20334658.
- McCall B (2005-12-28). "The ultimate hangover cure?". bbc.co.uk. Retrieved 2008-09-01.
- El Idrissi A, Okeke E, Yan X, Sidime F, Neuwirth LS (2013). "Taurine regulation of blood pressure and vasoactivity". Taurine 8. Advances in Experimental Medicine and Biology. 775. pp. 407–25. doi:10.1007/978-1-4614-6130-2_31. ISBN 978-1-4614-6129-6. PMID 23392950.
- Winiarska K, Szymanski K, Gorniak P, Dudziak M, Bryla J (February 2009). "Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits". Biochimie. 91 (2): 261–70. doi:10.1016/j.biochi.2008.09.006. PMID 18957317.
- Knopf K, Sturman JA, Armstrong M, Hayes KC (May 1978). "Taurine: an essential nutrient for the cat". The Journal of Nutrition. 108 (5): 773–8. doi:10.1093/jn/108.5.773. PMID 641594.
- Hayes KC, Carey RE, Schmidt SY (May 1975). "Retinal degeneration associated with taurine deficiency in the cat". Science. 188 (4191): 949–51. Bibcode:1975Sci...188..949H. doi:10.1126/science.1138364. PMID 1138364.
- "Taurine And Its Importance In Cat Foods". Iams Cat Nutrition Library. 2004. Archived from the original on 2006-10-19. Retrieved 2006-08-22.
- "Nutrient Requirements of Cats". Nutrient Requirements of Cats, Revised Edition, 1986. 1986. Archived from the original on 2006-09-01. Retrieved 2006-09-10.
- Pion PD, Kittleson MD, Rogers QR, Morris JG (August 1987). "Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy". Science. 237 (4816): 764–8. Bibcode:1987Sci...237..764P. doi:10.1126/science.3616607. PMID 3616607.
- "AAFCO CAT FOOD NUTRIENT PROFILES". Archived from the original on 2015-05-29. Retrieved 30 May 2015.
- Burger IH, Barnett KC (1982). "The taurine requirement of the adult cat". Journal of Small Animal Practice. 23 (9): 533–537. doi:10.1111/j.1748-5827.1982.tb02514.x.
- Arnold KE, Ramsay SL, Donaldson C, Adam A (October 2007). "Parental prey selection affects risk-taking behaviour and spatial learning in avian offspring" (PDF). Proceedings. Biological Sciences. 274 (1625): 2563–9. doi:10.1098/rspb.2007.0687. PMC 2275882. PMID 17698490.[permanent dead link]
- Shiva Shankar Reddy N, Jagan Mohanarao G, Atreja SK (June 2010). "Effects of adding taurine and trehalose to a tris-based egg yolk extender on buffalo (Bubalus bubalis) sperm quality following cryopreservation". Animal Reproduction Science. 119 (3–4): 183–90. doi:10.1016/j.anireprosci.2010.01.012. PMID 20197223.
- Mantovani J, DeVivo DC (November 1979). "Effects of taurine on seizures and growth hormone release in epileptic patients". Archives of Neurology. 36 (11): 672–4. doi:10.1001/archneur.1979.00500470042006. PMID 508122.
- Zackheim HS, Farber EM (March 1968). "Taurine and psoriasis". The Journal of Investigative Dermatology. 50 (3): 227–30. doi:10.1038/jid.1968.32. PMID 5644896. Retrieved 2013-11-23.
- Zackheim HS (1982). "Taurine and Diet in Psoriasis". Archives of Dermatology. 118 (12): 961. doi:10.1001/archderm.1982.01650240005005. PMID 7149750.
- Zackheim HS, Farber EM (May 1969). "Low-protein diet and psoriasis. A hospital study". Archives of Dermatology. 99 (5): 580–6. doi:10.1001/archderm.1969.01610230072012. PMID 5780964.
- Shao A, Hathcock JN (April 2008). "Risk assessment for the amino acids taurine, L-glutamine and L-arginine". Regulatory Toxicology and Pharmacology. 50 (3): 376–99. doi:10.1016/j.yrtph.2008.01.004. PMID 18325648.
the newer method described as the Observed Safe Level (OSL) or Highest Observed Intake (HOI) was utilized. The OSL risk assessments indicate that based on the available published human clinical trial data, the evidence for the absence of adverse effects is strong for Tau at supplemental intakes up to 3 g/d, Gln at intakes up to 14 g/d and Arg at intakes up to 20 g/d, and these levels are identified as the respective OSLs for normal healthy adults.
- "EFSA adopts opinion on two ingredients commonly used in some energy drinks". 12 February 2009. efsa.europa.eu.
- Clauson KA, Shields KM, McQueen CE, Persad N (2008). "Safety issues associated with commercially available energy drinks". Journal of the American Pharmacists Association. 48 (3): e55-63, quiz e64-7. doi:10.1331/JAPhA.2008.07055. PMID 18595815. S2CID 207262028.
- Collin C, Gautier B, Gaillard O, Hallegot P, Chabane S, Bastien P, et al. (August 2006). "Protective effects of taurine on human hair follicle grown in vitro". International Journal of Cosmetic Science. 28 (4): 289–98. doi:10.1111/j.1467-2494.2006.00334.x. PMID 18489269. S2CID 32840479.
We showed that taurine [...] prevented TGF-β1-induced deleterious effects on hair follicle.
- Janeke G, Siefken W, Carstensen S, Springmann G, Bleck O, Steinhart H, et al. (August 2003). "Role of taurine accumulation in keratinocyte hydration". The Journal of Investigative Dermatology. 121 (2): 354–61. doi:10.1046/j.1523-1747.2003.12366.x. PMID 12880428.
- James TJ, Hansen D, Nolfi J (2004-04-01). "Ocular Health and Next Generation Solutions". Optometric Management. Archived from the original on 2005-04-19. Retrieved 2008-01-10.
- Suzuki T, Suzuki T, Wada T, Saigo K, Watanabe K (December 2002). "Taurine as a constituent of mitochondrial tRNAs: new insights into the functions of taurine and human mitochondrial diseases". The EMBO Journal. 21 (23): 6581–9. doi:10.1093/emboj/cdf656. PMC 136959. PMID 12456664.
- Bünzli-Trepp U (2007). Systematic nomenclature of organic, organometallic and coordination chemistry. EPFL Press. p. 226. ISBN 9781420046151.